Tajuana Barron is the Vice President of Project Management responsible for project delivery. Ms. Barron joined PCM Trials in 2022 with over 30 years of clinical research experience working for Pharma companies and CROs.
Prior to joining PCM Trials, Ms. Barron served as a Senior Director of Project Management at PPD, where her responsibilities included oversight of a strategic partnership, DCT strategy and management of a team of project directors and managers. Previously, she held leadership roles at PRA and Schering Plough Research Institute. Ms. Barron earned a Bachelor of Science in Chemistry from Bennett College and studied at the University of Medicine & Dentistry of New Jersey.
Amber Hill, PhD, is a distinguished figure in the intersection of research, global community engagement, and AI technology. She is the founder and CEO of Research Grid (R.grid), a pioneering AI tech company that has developed an automation engine for admin-free clinical trials. Dr. Hill holds a PhD in Biomedical Neuroscience from University College London (UCL), where she also completed a postdoctoral fellowship focusing on widening access to research through AI, supplemented by a stint in Computer Science at Harvard University. Additionally, she has enhanced her leadership skills through a management program at MIT Sloan.
During her time as a student, Dr. Hill founded the nonprofit Movement for Hope, which engages in cross-disciplinary initiatives globally to raise awareness for neurological conditions and broaden access to research. At Research Grid, Dr. Hill leads the development of two innovation products -Inclusive and TrialEngine – which automates back-office tasks for engagement and clinical trials, respectively, streamlining processes to enhance efficiency and accessibility in medical research.
Michelle Mallitz, MD, is a Principal Investigator responsible for providing medical and clinical oversight of clinical trials at EmVenio’s community research sites. Dr. Mallitz joined EmVenio in 2023 with 25 years of experience in the medical field, with the past 11 years dedicated solely to clinical research. She has worked on over 130 clinical trials in a variety of therapeutic areas and is licensed in 5 states.
Prior to joining EmVenio Research, Dr. Mallitz served as an investigator for various research facilities, most recently at Care Access. Dr. Mallitz earned a Bachelor of Science degree in Molecular Biology from the University of Wisconsin, followed by a Master of Science degree in Human Physiology from Georgetown University and her doctorate from Georgetown University School of Medicine.
Christopher TS Harvey has spent the past two decades mastering the complexity of change and how to manage change successfully.
Since studying alongside Prince William and Kate at the University of St Andrews, Chris has been busy in the change space. Unaware at the time, he was somewhat of a trailblazer in the Change Management domain, obsessed with the human-centric, psychological nature of change. Pushing himself ever since to operate at the ‘bleeding edge’ of the change sphere.
What makes him a standout as a speaker is his ability to convert extensive academic understanding and hands on experience of complex change, into meaningful learnings and tangible takeaways for the audience to better manage through change. All done against a captivating backdrop of 80s/90s soundtracks, balloon metaphors and ‘tongue in cheek’ British humour.
Chris has been published extensively in GQ Magazine around the world, on change subjects ranging from natural disasters to workplace burnout. He’s also written for the Daily Mail, The Telegraph, HR Magazine, Business Insider, been interviewed by BBC, TalkRadio and many more. His proudest achievement will be publishing the book he continues to work on, whilst educating the next generation of change leaders through his guest lecturing.
With every editorial or speaking engagement, Chris’s aim always remains the same at its core: to ‘Demystify Change!’
Celine Vleer is a creative, visionary thinker with a passion for design and innovation. She played a crucial role in shaping the former Heineken Brewery in Amsterdam from a low-key visitor centre to the world-renowned Heineken Experience it is today.
With her love for storytelling and her ability to connect with consumers from all over the world ensure that each visitor leaves with fond memories and a deeper appreciation for the art of brewing. She has been with Heineken for over 15 years and had several brand design/brand building roles within the company.
Celine holds a bachelor in creative business from the University of Applied science in Amsterdam. She has served Heineken in both Amsterdam and in Singapore.
Donna Davidson is a master at building and nurturing creative partnerships. With over 25 years of experience developing successful and award-winning brand destinations and cultural attractions, she has an in-depth understanding of the process and necessary relationships to produce an on-schedule and on-budget opening and an enduring, profitable operation.
Based in the United Kingdom, Donna excels at studying the unique blend of culture, people, location, and theme of a project and then assembling a strong team of professionals to execute it. Some of her most notable clients and projects include Guinness Storehouse, Pilsner Urquell: The Original Beer Experience, Jameson Distillery Bow St., Johnnie Walker Princes Street, The Heineken Experience, Tusker EABL, Glenkinchie Distillery, Guinness Open Gate Brewery, and Clynelish Distillery.
Donna holds a Bachelor of Arts in History from the University of California, Los Angeles. She has served BRC both in the U.K. and Burbank, California offices.
Dr. Brannan is the former CMO at Karuna Therapeutics and a neuroscience drug development expert who has held senior positions overseeing both clinical development and medical affairs with more than 15 years of industry experience. Previously, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affairs at Forum Pharmaceuticals. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta, Exelon Patch, Trintellix, and VNS for Treatment Resistant Depression while holding various senior roles at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. His experience includes drug development, registration, medical affairs, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, migraine, cognition, and Alzheimer’s and Parkinson’s diseases. Dr. Brannan is a member of several scientific societies and groups, including ACNP, ISCTM (Member of both the Scientific and Executive Committees), ISCDD, AARR, IOM Neuroforum, and CNS Summit (founding member). Prior to joining the Pharmaceutical industry, Dr. Brannan worked on the faculty at the University of Texas Health Science Center at San Antonio (UTHSCSA) where he specialized in seeing Mood and Anxiety disorder patients, ran a clinical research unit, and did neuroimaging research at the Research Imaging Center. Dr. Brannan trained in psychiatry at UTHSCSA and holds a M.D. degree from the University of Texas Health Science Center at Dallas (Southwestern Medical School). He has over 50 publications and routinely gives invited talks and presentations at industry conferences.
Roger is an Associate Director in Deloitte’s Markets Assurance group, with a particular focus on algorithms and regulatory change. He has a deep understanding of algorithms, gained through over 20 years of experience in the UK and in Europe, and has a thorough technical knowledge of the regulatory landscape related to Artificial Intelligence. As a senior member of the Algorithm Assurance team, Roger has been a key figure in the design and development of Deloitte’s methodology for auditing AI. He has also supported numerous technology companies in their development of control frameworks for regulatory compliance as they move through this period of major change.
Is a well-recognized identity technology expert. He serves as the SVP, Head of Americas for iProov, a global provider of biometric authentication products used for online enrollment and verification. Ajay also serves as a strategic advisor for identity to leaders in e-commerce, artificial intelligence, and identity technology ranging from publicly-traded companies such as DocuSign (NASDAQ: DOCU) and PayPal (NASDAQ: PYPL), Credence ID, venture capital investors, and small to midsize disruptor companies. From 2019-2021, after his startup was acquired by Idemia (a $3B Paris-based identity technology company), he reported to the CEO and served as their SVP Corporate Strategy/Development and their GM of the Commercial Business Unit.
Miguel is responsible for the technology function in iProov, including engineering and platform and IT operations.
Prior to joining iProov, Miguel was Chief Information Officer for Operations and Economic Crime at Santander UK, where he had various engineering and transformation roles overseeing multi-disciplinary teams around the world.
He began his career with Accenture, running financial services projects in Europe and Latin America.
